Elements of cancer immunity and the cancer–immune set point
The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting that a broader view of cancer immunity is required. Immunity is influenced by a complex set of tumour, host and environmental factors that govern the strength and timing of the anticancer response. Clinical studies are beginning to define these factors as immune profiles that can predict responses to immunotherapy. In the context of the cancer-immunity cycle, such factors combine to represent the inherent immunological status - or 'cancer-immune set point' - of an individual.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This model effectively identifies two main clusters resembling the Immune-Inflamed and Immune-Desert phenotypes42–44”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [43]
In the citing paper
“Tumor-infiltrating lymphocytes (TILs) have been proven to be associated with immunotherapy response 245, OS, and PFS 246.”
From Artificial intelligence in pancreatic cancer (2022) · cites this paper as [245]
In the citing paper
“The microbiota influences the cancer-immune set point, which is the threshold beyond which an immune response can be elicited in a given individual.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [11]
In the citing paper
“Recently, it has been demonstrated that the efficacy of the treatment with immune checkpoint inhibitors can be influenced by the composition of the host gut microbiota (176).”
From Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019) · cites this paper as [176]
In the citing paper
“a variety of clinically relevant anticancer interventions including conventional chemotherapeutics (Galluzzi et al., 2020a), radiation therapy (RT) (Rodriguez-Ruiz et al., 2020), and targeted anticancer agents (see main text) have been shown to elicit bona fide ICD and hence jumpstart the cancer-immunity cycle (Chen and Mellman, 2017) in preclinical tumor models.”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chen and Mellman, 2017
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citation
Cited by
Items 401–500 of 1,026
Dendritic Cells in Cancer Immunology and Immunotherapy
Hato, L., Atienza, Á. V., Eguren‐Santamaría, I., Perez‐Gracia, J. L., Rodríguez, J., Pérez‐Larraya, J. G., Sarobe, P., Inogés, S., de Cerio, A. L. D., & Santisteban, M. (2024) · Cancers · doi:10.3390/cancers16050981 · Cited by 167
“…repair deficiency (dMMR), specific immune signatures such as interferon or APOBEC and tumor microenvironment (TME) composition and function (tumor infiltrating lymphocytes (TILs))—determine an inherent immunological status in cancer patients, as well as their response to immunotherapy [1–3].”
BackgroundXiang, Y., Liu, X., Wang, Y., Zheng, D., Meng, Q., Jiang, L., Yang, S., Zhang, S., Zhang, X., Liu, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366260 · Cited by 188
“Blocking CTLA-4 can directly target inhibitory signals on effector T cells and reduce the inhibitory effect of regulatory T cells (Tregs) (301 – 305) thus effectively enhancing the antitumor effect of T cells.”
BackgroundHuang, Y., Chen, Y., Zhou, S., Liang, C., Wang, J., Pei, Y., Xu, M., Feng, J., Jiang, T., Liang, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14425-7 · Cited by 145
Next-Generation Cancer Immunotherapy Targeting Glypican-3
Shimizu, Y., Suzuki, T., Yoshikawa, T., Endo, I., & Nakatsura, T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00248 · Cited by 144
“With the exception of Hodgkin’s lymphoma, response rates to ICIs are estimated as no more than 30% in the case of melanoma and 10–20% for other cancers (8, 9).”
BackgroundLi, B., Hao, G., Sun, B., Gu, Z., & Xu, Z. P. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909745 · Cited by 143
Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 154
Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities
Liu, Y., Zhou, X., & Wang, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01134-x · Cited by 151
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Fridman, W. H., Fucikova, J., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 136
Liu, J. F., Gordon, M. S., Veneris, J. T., Braiteh, F., Balmanoukian, A. S., Eder, J. P., Oaknin, A., Hamilton, E. P., Wang, Y., Sarkar, I., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.05.021 · Cited by 139
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
Sauer, N. J., Janicka, N., Szlasa, W., Skinderowicz, B., Kołodzińska, K., Dwernicka, W., Oślizło, M., Kulbacka, J., Novickij, V., & Karłowicz-Bodalska, K. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03516-1 · Cited by 158
“TIM-3 expression is found in all infiltrating cells present in breast cancer and correlates with other immune checkpoint inhibitors such as LAG-3, CTLA-4, and PD-1, which may underscore the importance of their interaction in the microenvironment [131, 134].”
BackgroundEnfield, K. S. S., Colliver, E., Lee, C., Magness, A., Moore, D. A., Sivakumar, M., Grigoriadis, K., Pich, O., Karasaki, T., Hobson, P. S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1380 · Cited by 151
“We defined four distinct, pan-histology TME classes in early-stage treatment-naïve NSCLC, building on earlier classifications based on the spatial distribution of TILs alone (17) and compositional clustering from gene expression (38–40).”
Infiltration of CD8 + T cells into tumor cell clusters in triple-negative breast cancer
Li, X., Gruosso, T., Zuo, D., Omeroglu, A., Meterissian, S., Guiot, M.-C., Salazar, A., Park, M., & Levine, H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817652116 · Cited by 134
Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging
Du, Z., Lin, J.-R., Rashid, R., Maliga, Z., Wang, S., Aster, J. C., Izar, B., Sorger, P. K., & Santagata, S. (2019) · Nature Protocols · doi:10.1038/s41596-019-0206-y · Cited by 134
Molecular subtypes and precision treatment of triple-negative breast cancer
Zhao, S., Zuo, W., Shao, Z., & Jiang, Y. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.194 · Cited by 153
“The TME has been increasingly recognized as an important indicator for patient prognosis and the efficacy of immunotherapy (49,50).”
BackgroundPrognostic analysis of cuproptosis-related gene in triple-negative breast cancer
Sha, S., Si, L., Wu, X., Chen, Y., Xiong, H., Xu, Y., Liu, W., Mei, H., Wang, T., & Li, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.922780 · Cited by 147
“CRG cluster B, however, was more in line with an immunoinflammatory phenotype because of the large degree of immune cell infiltration in the TME (36).”
BackgroundLaubli, H. P., Balmelli, C., Kaufmann, L., Stanczak, M. A., Syedbasha, M., Vogt, D., Hertig, A., Müller, B. P., Gautschi, O. P., Stenner, F., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0353-7 · Cited by 142
“Therapeutic vaccination for cancer is currently tested in many clinical trials together with immune checkpoint inhibitors [9, 47].”
BackgroundImmune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells
Tucci, M., Passarelli, A. M., Mannavola, F., Felici, C., Stucci, L. S., Cives, M., & Silvestris, F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01148 · Cited by 154
“Their cellular and molecular properties are pivotal determinants of both melanoma progression and also therapeutic response (57).”
BackgroundSex Hormones and Anticancer Immunity
Özdemir, B. C., & Dotto, G.-P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0137 · Cited by 132
Brenner, E., Schörg, B. F., Ahmetlić, F., Wieder, T., Hilke, F. J., Simon, N., Schroeder, C., Demidov, G. M., Riedel, T., Fehrenbacher, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14987-6 · Cited by 147
Spatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment
Wang, N., Li, X., Wang, R., & Ding, Z. (2021) · Biotechnology Journal · doi:10.1002/biot.202100041 · Cited by 146
Hernandez, S., Qing, J., Hong, R., Du, X., Park, S., Lee, H.-M., Xu, M., Oh, S. A., Navarro, A., Roose-Girma, M., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.012 · Cited by 136
Self-citationHypophysitis induced by immune checkpoint inhibitors: a 10-year assessment
Dalmazi, G. D., Ippolito, S., Lupi, I., & Caturegli, P. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1701434 · Cited by 138
“this area of medicine, expanding the assessment previously made by Chen and Mellman [9].”
ResultFu, Z., Mowday, A. M., Smaill, J. B., Hermans, I. F., & Patterson, A. V. (2021) · Cells · doi:10.3390/cells10051006 · Cited by 147
“, impact of sex and age on immunity) [10,11,16,17].”
BackgroundYong, T., Wei, Z., Gan, L., & Yang, X. (2022) · Advanced Materials · doi:10.1002/adma.202201054 · Cited by 130
Wang-Bishop, L., Kimmel, B. R., Ngwa, V. M., Madden, M. Z., Baljon, J. J., Florian, D. C., Hanna, A., Pastora, L. E., Sheehy, T. L., Kwiatkowski, A. J., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add1153 · Cited by 126
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
Moya‐Horno, I., Viteri, S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017745012 · Cited by 139
Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy
Tu, M. M., Lee, F. Y., Jones, R. T., Kimball, A. K., Saravia, E., Graziano, R. F., Coleman, B. M., Menard, K., Yan, J., Michaud, E., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav2437 · Cited by 141
“While this growth indicates the excitement surrounding immune-focused treatment modalities, it has also markedly outpaced the gathering of preclinical evidence supporting them (4).”
BackgroundPathogenesis of Giant Cell Arteritis and Takayasu Arteritis—Similarities and Differences
Watanabe, R., Berry, G. J., Liang, D. H., Goronzy, J. J., & Weyand, C. M. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00948-x · Cited by 149
Tolerance in the Age of Immunotherapy
Bluestone, J. A., & Anderson, M. S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1911109 · Cited by 150
Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide
Kim, S. S., Harford, J. B., Moghe, M., Rait, A. S., Pirollo, K. F., & Chang, E. H. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1221 · Cited by 135
VISTA: Coming of age as a multi-lineage immune checkpoint
ElTanbouly, M. A., Schaafsma, E., Noelle, R. J., & Lines, J. L. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13415 · Cited by 126
Li, S., Sun, Y., Huang, J., Wang, B., Gong, Y., Fang, Y., Liu, Y., Wang, S., Guo, Y., Wang, H., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112797 · Cited by 139
PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
Khasraw, M., Reardon, D. A., Weller, M., & Sampson, J. H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1135 · Cited by 143
“A tumor that is characterized as an immune desert can arise from immune ignorance, tolerance, or absence of Tcell priming or activation (14).”
BackgroundThe link between kidney disease and cancer: complications and treatment
Małyszko, J., Tesařová, P., Capasso, G., & Capasso, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30540-7 · Cited by 149
Wehbe, M., Wang-Bishop, L., Becker, K. W., Shae, D., Baljon, J. J., He, X., Christov, P. P., Boyd, K. L., Balko, J. M., & Wilson, J. T. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.017 · Cited by 132
Role of mTOR Signaling in Tumor Microenvironment: An Overview
Conciatori, F., Bazzichetto, C., Falcone, I., Pilotto, S., Bria, E., Cognetti, F., Milella, M., & Ciuffreda, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082453 · Cited by 138
“responses; CTLA-4 is a negative regulator of T cells, by competing with the co-stimulatory molecule CD28 for the binding to the ligands CD80 and CD86 [113].”
BackgroundChen, J., Ye, X., Pitmon, E., Lu, M., Wan, J., Jellison, E. R., Adler, A. J., Vella, A. T., & Wang, K. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0757-z · Cited by 146
Williford, J.-M., Ishihara, J., Ishihara, A., Mansurov, A., Hosseinchi, P., Marchell, T. M., Potin, L., Swartz, M. A., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aay1357 · Cited by 127
Wu, J., Chen, J., Feng, Y., Zhang, S., Lın, L., Guo, Z., Sun, P., Xu, C., Tian, H., & Chen, X. (2020) · Science Advances · doi:10.1126/sciadv.abc7828 · Cited by 128
“In addition, reversing the immunosuppressive TME is also important because it would continuously exhaust the intratumoral T cells, whether they were preexisting or newly infiltrated (19).”
BackgroundLing, Y., Xia, X., Liang, H., Wang, W., Zhang, H., Liu, L., Liu, W., Li, Z., Tan, C., & Mao, Z. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202210988 · Cited by 134
Dutta, S., Ganguly, A., Chatterjee, K., Spada, S., & Mukherjee, S. (2023) · Biology · doi:10.3390/biology12020218 · Cited by 153
Wu, Y., Yi, Z., Li, J., Wei, Y., Feng, R., Liu, J., Huang, J., Chen, Y., Wang, X., Sun, J., et al. (2022) · Theranostics · doi:10.7150/thno.68972 · Cited by 134
“The immune-desert subtype and the immune-excluded subtype are both regarded as non-inflamed “cold” tumors [1].”
BackgroundInfluentialStress and cancer: The mechanisms of immune dysregulation and management
Liu, Y., Tian, S., Ning, B., Huang, T., Li, Y., & Wei, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032294 · Cited by 181
Inflammation in cancer: therapeutic opportunities from new insights
Xie, Y., Liu, F., Wu, Y., Zhu, Y., Jiang, Y., Wu, Q., Dong, Z., & Liu, K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02243-8 · Cited by 167
Macrophage-Targeted Therapeutics for Metabolic Disease
Peterson, K. R., Cottam, M. A., Kennedy, A. J., & Hasty, A. H. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.001 · Cited by 124
“Their roles in autoimmune and inflammatory diseases are obvious; however, more recently, their contributions to cancer [1], cardiovascular disease [2, 3], and diabetes [4–6], have also been elucidated.”
BackgroundThe Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer
van Dijk, N., Funt, S. A., Blank, C. U., Powles, T. B., Rosenberg, J. E., & van der Heijden, M. S. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.022 · Cited by 125
Mazzaschi, G., Facchinetti, F., Missale, G., Canetti, D., Madeddu, D., Zecca, A., Veneziani, M., Gelsomino, F., Goldoni, M., Buti, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.038 · Cited by 134
Bergerot, P., Lamb, P., Wang, E., & Pal, S. K. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1399 · Cited by 124
“org Mol Cancer Ther; 18(12) December 2019 2187”
BackgroundInfluentialPauken, K. E., Godec, J., Odorizzi, P. M., Brown, K. E., Yates, K. B., Ngiow, S. F., Burke, K. P., Maleri, S., Grande, S. M., Francisco, L. M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107827 · Cited by 122
Farwell, M. D., Gamache, R. F., Babazada, H., Hellmann, M. D., Harding, J. J., Korn, R. L., Mascioni, A., Le, W., Wilson, I., Gordon, M. S., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262485 · Cited by 170
“…had radiotracer activity at background, demonstrating that 89 Zr-Df-IAB22M2C has low nonspeci fi c uptake and thus has the potential to quantify CD8 1 leukocytes across a wide dynamic range, including those with few to no CD8 1 cells, often termed “ immune desert ” on histologic appearance ( 24 ).”
BackgroundKilian, M., Sheinin, R., Tan, C. L., Friedrich, M., Krämer, C., Kaminitz, A., Sanghvi, K., Lindner, K. A. M., Chih, Y., Cichon, F., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.007 · Cited by 135
Long noncoding RNAs in cancer‐immunity cycle
Yu, W., Wang, H., He, Q., Xu, Y., & Wang, X. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26568 · Cited by 132
“Based on this, a new frame named “cancer-immune set point” has been put forward for further studies in both clinical therapies and fundamental researches (Chen & Mellman, 2017).”
BackgroundThe phosphatase PAC1 acts as a T cell suppressor and attenuates host antitumor immunity
Lü, D., Liu, L., Sun, Y., Song, J., Yin, Q., Zhang, G., Fang, Q., Hu, Z., Yang, Z., Zhou, Z. C., et al. (2020) · Nature Immunology · doi:10.1038/s41590-019-0577-9 · Cited by 123
Jiang, Z., Huang, J., Xie, Y., Zhang, Y. Z., Chang, C., Lai, H., Wang, W., Yao, X., Fan, X., Wu, Q., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01741-5 · Cited by 137
Mpakali, A., & Stratikos, E. (2021) · Cancers · doi:10.3390/cancers13010134 · Cited by 138
Siglec receptors as new immune checkpoints in cancer
Stanczak, M. A., & Laubli, H. P. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101112 · Cited by 144
High endothelial venules in cancer: Regulation, function, and therapeutic implication
Vella, G., Hua, Y., & Bergers, G. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.002 · Cited by 138
Immunosurveillance in clinical cancer management
Kroemer, G., Chan, T. A., Eggermont, A. M. M., & Galluzzi, L. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21818 · Cited by 123
“17,18 The three Es are also reflected in the means by which we inter-vene against cancer.”
BackgroundSelective inhibition of low-affinity memory CD8(+) T cells by corticosteroids
Tokunaga, A., Sugiyama, D., Maeda, Y., Warner, A. B., Panageas, K. S., Ito, S., Togashi, Y., Sakai, C., Wolchok, J. D., & Nishikawa, H. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190738 · Cited by 124
“…of various immunosuppressive molecules, and induction/recruitment of immunosuppressive cells (e.g., myeloid-derived suppressor cells, tumor-associated macrophages, and regulatory T cells), impairing the development of antitumor immune responses (Pitt et al., 2016; Chen and Mellman, 2017).”
The role of tumor-infiltrating lymphocytes in cholangiocarcinoma
Liu, D., Heij, L. R., Czigány, Z., Dahl, E., Lang, S. A., Ulmer, T. F., Luedde, T., Neumann, U. P., & Bednarsch, J. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02340-2 · Cited by 134
“Research has shown that anticancer drugs that are rationally selected for triggering tumor immunogenicity can be used to make resistant tumors sensitive to checkpoint blockade therapy [91, 92].”
BackgroundCurrent trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 160
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 133
Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration
Lim, Y. W., Chen-Harris, H., Mayba, O., Lianoglou, S., Wuster, A., Bhangale, T., Khan, Z., Mariathasan, S., Daemen, A., Reeder, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804506115 · Cited by 121
“The rapidly emerging field of cancer immunotherapy aims to tip the balance by harnessing the host immune response(s); however, despite significant successes, only a subset of patients benefits from durable responses (3).”
BackgroundSelf-citationmTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion
Liu, H.-J., Du, H., Khabibullin, D., Zarei, M., Wei, K., Freeman, G. J., Kwiatkowski, D. J., & Henske, E. P. (2023) · Nature Communications · doi:10.1038/s41467-023-36881-7 · Cited by 139
“o Representative images and quantification of CD38CD39CD4 TILs in sh-NC, sh-B7-H3 (1), or sh-B7-H3 (2) Tsc2−/− 105K”
BackgroundMethodInfluentialImmune checkpoint inhibitors in advanced non–small cell lung cancer
Assi, H. I., Kamphorst, A. O., Moukalled, N. M., & Ramalingam, S. S. (2018) · Cancer · doi:10.1002/cncr.31105 · Cited by 121
“The Bristol-Myers Squibb (BMS)-026 study compared nivolumab versus chemotherapy in advanced NSCLC.”
BackgroundInfluentialSobral‐Leite, M., de Vijver, K. K. V., Michaut, M., van der Linden, R., Hooijer, G. K. J., Horlings, H. M., Severson, T., Mulligan, A. M., Weerasooriya, N., Sanders, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1509820 · Cited by 136
“tumor cells contributes to the tumor infiltration of immune cells and PD-L1 expression.(3,31) Moreover, the association between PD-L1 expression and prognosis of breast cancer remains controversial.”
BackgroundZhou, G., Sprengers, D., Mancham, S., Erkens, R. G. A., Boor, P. P. C., van Beek, A. A., Doukas, M., Noordam, L., Carrascosa, L. C., de Ruiter, V., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.026 · Cited by 128
Tuning the Tumor Myeloid Microenvironment to Fight Cancer
Jahchan, N. S., Mujal, A. M., Pollack, J. L., Binnewies, M., Sriram, V., Reyno, L., & Krummel, M. F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01611 · Cited by 120
“Only about 25% of patients across all indications respond to ICB therapies, highlighting the importance for additional therapies to treat the remaining nonresponsive patients (14).”
BackgroundMultiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity
Wang, G., Chow, R. D., Bai, Z., Zhu, L., Errami, Y., Dai, X., Dong, M. B., Ye, L., Zhang, X., Renauer, P. A., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0500-4 · Cited by 119
Liu, Y., Yang, Q., Yang, J., Cao, R., Liang, J., Liu, Y., Zeng, Y., Chen, S., Xia, X., Zhang, K., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32145 · Cited by 134
“Patients with low TCR diversity may have a severely impaired immune status, which is a potential negative predictor for ICB response.(20,34,35) The potential for patients with low TCR diversity to respond poorly to ICB is supported by the relationship of diversity with LDH, NLR, and TP53 mutation.”
BackgroundROS: A “booster” for chronic inflammation and tumor metastasis
Chen, A., Huang, H., Fang, S., & Hang, Q. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189175 · Cited by 151
Rini, B. I., McDermott, D. F., Hammers, H. J., Bro, W., Bukowski, R. M., Faba, B., Faba, J., Figlin, R. A., Hutson, T. E., Jonasch, E. W., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0180-7 · Cited by 125
Barta, S. K., Zain, J. M., Macfarlane, A. W., Smith, S. M., Ruan, J., Fung, H. C. H., Tan, C. R. C., Yang, Y., Alpaugh, R. K., Dulaimi, E., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.03.022 · Cited by 133
Vascular Normalization: A New Window Opened for Cancer Therapies
Yang, T., Xiao, H., Liu, X., Wang, Z., Zhang, Q., Wei, N., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719836 · Cited by 141
Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach
Ghisoni, E., Morotti, M., Sarivalasis, A., Grimm, A. J., Kandalaft, L. E., Laniti, D. D., & Coukos, G. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00937-4 · Cited by 141
Tasdogan, A., Sullivan, R. J., Katalinic, A., Lebbé, C., Whitaker, D., Puig, S., van de Poll-Franse, L. V., Massi, D., & Schadendorf, D. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00603-8 · Cited by 169
Wu, C., Guan, X., Xu, J., Zhang, Y., Liu, Q., Tian, Y., Li, S., Qin, X., Yang, H., & Liu, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.03.020 · Cited by 117
NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target
Gambella, A., Senetta, R., Collemi, G., Vallero, S. G., Monticelli, M., Cofano, F., Zeppa, P., Garbossa, D., Pellerino, A., Rudà, R., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030753 · Cited by 127
New viral vectors for infectious diseases and cancer
Sasso, E., D’Alise, A. M., Zambrano, N., Scarselli, E., Folgori, A., & Nicosia, A. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101430 · Cited by 134
“mors defined as immune-excluded and immune-desert [219,220].”
The role of tumor-associated macrophages in osteosarcoma progression – therapeutic implications
Huang, Q., Liang, X., Ren, T., Huang, Y., Zhang, H., Yu, Y., Chen, C., Wang, W., Niu, J., Lou, J., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00598-w · Cited by 118
Yi, Y., Yu, M., Feng, C., Hao, H., Zeng, W., Lin, C., Chen, H., Lv, F., Zhu, D., Ji, X., et al. (2022) · Matter · doi:10.1016/j.matt.2022.04.032 · Cited by 121
Parascandolo, A., & Laukkanen, M. O. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7268 · Cited by 116
“In the later phases of carcinogenesis, cancer cells have been shown to educate inflammatory cells toward the protumorigenic mode, indicating the ability of cancer cells to adapt and utilize host tissue defense functions (46).”
BackgroundTIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer
Fucikova, J., Rakova, J., Hensler, M., Kasikova, L., Belicova, L., Hladikova, K., Truxova, I., Skapa, P., Laco, J., Pecen, L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4175 · Cited by 117
Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment
Pauken, K. E., Shahid, O., Lagattuta, K. A., Mahuron, K. M., Luber, J. M., Lowe, M. M., Huang, L., Delaney, C., Long, J. M., Fung, M. E., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20200920 · Cited by 124
“Cancer immunotherapy has revolutionized treatment of many solid and liquid tumors (Chen and Mellman, 2017; Ribas and Wolchok, 2018; Sharma and Allison, 2015; Sharpe and Pauken, 2018; Sun et al., 2018).”
BackgroundPowles, T. B., Sridhar, S. S., Loriot, Y., Bellmunt, J., Mu, X. J., Ching, K. A., Pu, J., Sternberg, C. N., Petrylak, D. P., Tambaro, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01579-0 · Cited by 122
Joung, J., Kirchgatterer, P. C., Singh, A., Cho, J. H., Nety, S. P., Larson, R. C., Macrae, R. K., Deasy, R., Tseng, Y., Maus, M. V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29205-8 · Cited by 128
Abdul‐Rahman, T., Ghosh, S., Badar, S. M., Nazir, A., Bamigbade, G. B., Aji, N., Roy, P., kachani, H., Garg, N. K., Lawal, L., et al. (2024) · European journal of medical research · doi:10.1186/s40001-024-01711-z · Cited by 152
“This complexity can limit the efficacy of cytokine therapies, as the cytokines may not be able to penetrate the TME or may be counteracted by other signaling pathways [154].”
BackgroundWang, C., Yin, R., Dai, J., Gu, Y., Cui, S., Ma, H., Zhang, Z., Huang, J., Qin, N., Jiang, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04492-2 · Cited by 116
Zheng, J., Wu, M. H., Wang, H., Li, S., Wang, X., Li, Y., Wang, D., & Li, S. (2018) · Cancers · doi:10.3390/cancers10110461 · Cited by 135
“Even though immune evasion is one of cancer’s hallmarks, it characterizes the responses using the immune system [62].”
Backgroundde la Iglesia, J. V., Slebos, R. J. C., Martin‐Gomez, L., Wang, X., Teer, J. K., Tan, A. C., Gerke, T. A., Aden-Buie, G., van Veen, T., Masannat, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1769 · Cited by 127
“These disease site–specific data are particularly important in context of the cancer–immune set point, the threshold needed to mount effective cancer immunity (49).”
BackgroundNanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy
Zhu, Y., Yu, X., Thamphiwatana, S., Zheng, Y., & Pang, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.08.010 · Cited by 118
Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution
Calligaris, M., Cuffaro, D., Bonelli, S., Spanò, D. P., Rossello, A., Nuti, E., & Scilabra, S. D. (2021) · Molecules · doi:10.3390/molecules26040944 · Cited by 130
“PD-L1 is a type one transmembrane protein, expressed at high levels in several human cancers and playing a major role in suppressing adaptive immune responses [161].”
BackgroundTargeting the tumor biophysical microenvironment to reduce resistance to immunotherapy
Zhang, T., Jia, Y., Yu, Y., Zhang, B., Xu, F., & Guo, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114319 · Cited by 113
Puttock, E. H., Tyler, E. J., Manni, M., Maniati, E., Butterworth, C., Ramos, M. B., Peerani, E., Hirani, P., Gauthier, V., Liu, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38093-5 · Cited by 139
“1G), a series of seven step-wise events that help inform how an immune response can be activated against an established tumor 29 .”
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
“These tumors are marked by an inability of T cells to penetrate the tumor parenchyma, remaining instead in the tumor stroma ( ‘ immune-excluded ’ ) or by a lack of T cell in fi ltration in both the tumor parenchyma and stroma ( ‘ immune-desert ’ ) (3).”
BackgroundChang, C., Park, H., Malone, D. C., Wang, C.-Y., Wilson, D. L., Yeh, Y., van Boemmel-Wegmann, S., & Lo-Ciganic, W.-H. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.1611 · Cited by 128
Turning tumors from cold to inflamed to improve immunotherapy response
Gerard, C. L., Delyon, J., Wicky, A. M., Homicskó, K., Cuendet, M. A., & Michielin, O. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102227 · Cited by 131
PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy
Cottrell, T. R., & Taube, J. M. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000301 · Cited by 129
“This complex and evolving landscape has been recently covered in detail elsewhere.(37,49,50) Effective T-cell antigen recognition, priming, tumor infiltration, and cytotoxic effector function are all necessary steps for tumor elimination and potential targets of therapeutic intervention.”
BackgroundBrooks, J. M., de Menezes, A. N., Ibrahim, M., Archer, L., Lal, N., Bagnall, C. J., von Zeidler, S. V., Valentine, H. R., Spruce, R. J., Batis, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3314 · Cited by 125
“Previous studies in diverse tumor settings have correlated response to immune checkpoint blockade (particularly involving the PD-1/PD-L1 axis) with "cancer immune phenotype" (25).”
BackgroundResident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients
Egelston, C. A., Avalos, C., Tu, T. Y., Rosario, A., Wang, R., Solomon, S. T., Srinivasan, G., Nelson, M. S., Huang, Y., Lim, M. H., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130000 · Cited by 164
“Tumors may also be divided by their immune infiltration profiles: immune-inflamed, immuneexcluded, and immune-desert (9).”
Background
Metadata
- Authors
- Chen, D. S., & Mellman, I.
- Affiliations
- Genentech (US)
- Corresponding author
- Mellman, Ira
- Venue
- Nature
- Published
- 2017-01
- Volume
- 541
- Issue
- 7637
- Pages
- 321-330
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2578528809
- Cited by
- 5,352
- References
- 121
- Citations by year
- 2026: 524 · 2025: 527 · 2024: 626 · 2023: 708 · 2022: 848 · 2021: 681 · 2020: 582 · 2019: 386 · 2018: 335 · 2017: 131
- FWCI
- 41.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- antitumor immunity, cancer-immunity cycle, immunotherapy response, CTLA-4, PD-1/PD-L1, immune checkpoint inhibitors, tumor immune microenvironment, immunological profile, predictive biomarkers, durable response
- MeSH terms
- Animals, Humans, Immunologic Memory, Immunotherapy, Inflammation, Neoplasms, T-Lymphocytes, Genome, Human, Tumor Escape, Epigenesis, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.